or Try an Advanced Search...

    Technical Analysis for EQ - Equillium, Inc.

    Grade Last Price % Change Price Change
    F 0.68 -2.21% -0.02
    EQ closed down 2.21 percent on Monday, July 1, 2024, on 9 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Flat
    Historical EQ trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -2.21%
    Oversold Stochastic Weakness -2.21%
    Narrow Range Bar Range Contraction 1.48%
    Wide Bands Range Expansion 1.48%
    Oversold Stochastic Weakness 1.48%
    Older End-of-Day Signals for EQ ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    60 Minute Opening Range Breakdown about 7 hours ago
    Down 3% about 7 hours ago
    10 DMA Support about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    EQ Chart by TradingView
    Basic chart:

    Profile

    Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders

    Is EQ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 12 Equillium to join Russell Microcap Index
    Jun 12 Equillium to be included in the Russell Microcap® Index
    Jun 4 Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings
    Jun 4 Equillium posts early mid-stage data for hair loss therapy
    Jun 4 Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
    May 29 Equillium to Present at the Jefferies Global Healthcare Conference
    May 14 Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
    May 9 Equillium GAAP EPS of -$0.08, revenue of $10.7M
    May 9 Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
    May 9 Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
    See more EQ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.25
    52 Week Low 0.45
    Average Volume 378,448
    200-Day Moving Average 1.22
    50-Day Moving Average 1.26
    20-Day Moving Average 0.78
    10-Day Moving Average 0.68
    Average True Range 0.09
    RSI (14) 29.08
    ADX 47.05
    +DI 13.22
    -DI 31.43
    Chandelier Exit (Long, 3 ATRs) 1.26
    Chandelier Exit (Short, 3 ATRs) 0.90
    Upper Bollinger Bands 1.15
    Lower Bollinger Band 0.40
    Percent B (%b) 0.37
    BandWidth 95.82
    MACD Line -0.19
    MACD Signal Line -0.21
    MACD Histogram 0.0253
    Fundamentals Value
    Market Cap 23.81 Million
    Num Shares 35.1 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -3.08
    Price-to-Sales 1.27
    Price-to-Book 2.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.71
    Resistance 3 (R3) 0.71 0.70 0.71
    Resistance 2 (R2) 0.70 0.69 0.70 0.71
    Resistance 1 (R1) 0.69 0.69 0.69 0.69 0.70
    Pivot Point 0.68 0.68 0.68 0.68 0.68
    Support 1 (S1) 0.67 0.67 0.66 0.67 0.65
    Support 2 (S2) 0.66 0.67 0.66 0.65
    Support 3 (S3) 0.64 0.66 0.65
    Support 4 (S4) 0.64